Search results
Results from the WOW.Com Content Network
Acebutolol, [1] sold under the brand names Sectral among others, is a beta blocker for the treatment of hypertension and arrhythmias. Acebutolol is a cardioselective beta-1 blocker and has intrinsic sympathetic activity. It is commonly used in the treatment of angina. It was patented in 1967 and approved for medical use in 1973. [2]
Antihypertensive agents comprise multiple classes of compounds that are intended to manage hypertension (high blood pressure). Antihypertensive therapy aims to maintain a blood pressure goal of <140/90 mmHg in all patients, as well as to prevent the progression or recurrence of cardiovascular diseases (CVD) in hypertensive patients with established CVD. [2]
Betaxolol is most commonly ingested orally alone or with other medications for the management of essential hypertension. [4] It is a cardioselective beta blocker, targeting beta-1 adrenergic receptors found in the cardiac muscle. Blood pressure is decreased by the mechanism of blood vessels relaxing and improving the flow of blood. [5] [6]
Beta blockers are widely used for the treatment of hypertension. [24] A 2014 Cochrane review found that in individuals with mild-to-moderate hypertension, non-selective beta blockers led to a reduction of -10/-7mmHg (systolic/diastolic) without increased rates of adverse events. [25]
6 Mixed alpha + beta blockers. 7 Calcium channel blockers. 8 Antimineralocorticoid. 9 Antiplatelet drug. 10 Anticoagulant. 11 Fibrinolytics. 12 Diuretics. 13 References.
CAD: add beta-blocker Resistant hypertension: add spironolactone ACC / AHA 2017 [13] General <130/80 BP > 130/80: Lifestyle changes and monotherapy with thiazide-type diuretic, ACEI/ARB, and/or CCB BP >20/10 above target: Lifestyle changes and two from different classes: thiazide-type diuretic, ACEI/ARB, and/or CCB JNC 8 2013 [1] General age ≥60
In particular, beta-blockers are no longer recommended as first-line treatment due to relative adverse risk of stroke and new-onset of type 2 diabetes when compared to other medications, [3] while certain specific beta-blockers such as atenolol appear to be less useful in overall treatment of hypertension than several other agents. [36]
[11] [28] Compared to placebo, beta-blockers have a greater benefit in stroke reduction, but no difference on coronary heart disease or all-cause mortality. [32] However, three-quarters of active beta-blocker treatments in the randomised controlled trials included in the review used atenolol, and none used the newer vasodilating beta-blockers. [33]